 Pfizer Inc. has reached a $35 million settlement with 41 states and the District of Columbia over alleged improper marketing of its drug Rapamune, New York Attorney General Eric Schneiderman said Wednesday. . The states said Pfizer unit Wyeth Pharmaceuticals Inc. promoted the drug, which is approved by the Food and Drug Administration to prevent bodies from rejecting kidney transplants, for other uses that weren't approved by the regulator. 